Author: Eunoia Consulting Co. | Published: July 1, 2026
Healthcare organisations are deploying AI faster than governance structures can keep pace. This practical roadmap shows clinical and operational leaders exactly how to build a defensible AI governance framework — from risk classification to board-level accountability.
Healthcare has always operated under a governance imperative. Clinical protocols, credentialing requirements, and accreditation standards exist precisely because the consequences of failure are measured in patient outcomes, not quarterly earnings. Yet when artificial intelligence entered the clinical environment — through diagnostic imaging algorithms, predictive deterioration models, and automated prior authorisation tools — many organisations deployed first and governed later.
That approach is no longer viable. The FDA has cleared over 950 AI-enabled medical devices as of mid-2025, and the pace of deployment is accelerating. Simultaneously, the regulatory environment is tightening: the EU AI Act has classified most clinical AI as high-risk, the FTC has issued guidance on algorithmic accountability, and CMS is actively reviewing how AI-assisted coding and documentation tools interact with billing compliance. Organisations that lack a formal governance structure are accumulating regulatory and reputational risk with every model they deploy.
This article provides a practical roadmap for healthcare organisations building or maturing their AI governance framework in 2025.
Effective AI governance in healthcare is not a single policy document. It is a structured architecture with four interdependent layers.
Layer 1: Policy and Principles. The foundation is a set of organisational AI principles that articulate the values guiding every deployment decision. These principles should address fairness and bias, transparency and explainability, patient safety primacy, data privacy, and human oversight. Critically, they must be operationalised — not aspirational statements that live in a PDF no one reads.
Layer 2: Risk Classification. Not all AI systems carry equal risk. A scheduling optimisation tool and a sepsis prediction model require fundamentally different oversight. Your framework must include a risk classification methodology that assigns each AI system to a tier — typically low, medium, or high risk — based on clinical impact, autonomy level, and data sensitivity. The NIST AI Risk Management Framework (AI RMF 1.0) provides the most widely adopted voluntary standard for this classification work in US healthcare.
Layer 3: Oversight and Accountability. Every AI system in clinical or operational use must have a named owner accountable for its performance and compliance. This layer defines the governance committee structure (typically an AI Ethics Committee or Clinical AI Review Board), the role of the AI Ethics Officer or equivalent, and the escalation pathways when a model behaves unexpectedly. Board-level visibility into high-risk AI deployments is increasingly expected under emerging federal guidance.
Layer 4: Monitoring, Audit, and Incident Response. Governance does not end at deployment. Post-market surveillance for clinical AI is an active area of FDA guidance development, and organisations should establish continuous monitoring protocols, periodic bias audits, and a documented incident response process for AI-related adverse events.
The NIST AI Risk Management Framework, released in January 2023, has become the de facto voluntary standard for AI governance in US healthcare. Its four core functions — Govern, Map, Measure, and Manage — map directly onto the four-layer architecture described above.
> "The AI RMF is intended to build on, align with, and support AI risk management efforts by others, and to be used in conjunction with other risk management frameworks." — NIST AI RMF 1.0
The Govern function establishes the organisational policies, culture, and accountability structures. The Map function identifies and classifies AI risks in context. The Measure function deploys tools and methodologies to quantify those risks. The Manage function implements controls, monitors performance, and responds to incidents.
Healthcare organisations that have already invested in ISO 27001 or SOC 2 compliance will find significant overlap with the NIST AI RMF, particularly in the risk identification and control documentation requirements.
Step 1: Inventory your AI systems. Most organisations are surprised by how many AI tools are already in use — embedded in EHR platforms, clinical decision support modules, revenue cycle management software, and third-party applications. A complete inventory is the prerequisite for everything that follows.
Step 2: Classify by risk tier. Apply your risk classification methodology to every system in the inventory. High-risk systems — those that directly influence clinical decisions or patient safety — require the most rigorous governance controls.
Step 3: Assign ownership and accountability. Every system needs a named owner: a clinical champion responsible for performance and a technical owner responsible for model maintenance. High-risk systems require executive sponsorship and board visibility.
Step 4: Establish your oversight committee. A Clinical AI Review Board or AI Ethics Committee should include representation from clinical leadership, legal and compliance, IT and data science, patient advocacy, and operations. This committee reviews new deployments, monitors high-risk systems, and adjudicates escalations.
Step 5: Implement continuous monitoring. Define the key performance indicators for each AI system — accuracy metrics, bias indicators, utilisation rates, and clinical outcome correlations. Establish the cadence for review and the thresholds that trigger escalation.
Step 6: Document everything. Governance without documentation is not governance. Maintain a model registry, risk assessments, audit logs, and incident reports. This documentation is your defence in a regulatory inquiry and your evidence base for continuous improvement.
One of the most common gaps Eunoia Consulting Co. observes in healthcare AI governance assessments is the absence of a named AI Ethics Officer or equivalent role. Many organisations have a Chief Information Officer and a Chief Medical Officer, but no one whose primary responsibility is the ethical and regulatory governance of AI systems.
This is not a gap that can be filled by a committee. Committees deliberate; they do not own. The AI Ethics Officer role — whether a dedicated position or a formal designation within an existing role — provides the single point of accountability that regulators, accreditors, and patients will increasingly expect.
Building an AI governance framework is not a one-time project. It is an ongoing operational capability that must evolve as your AI portfolio grows and the regulatory environment matures. Organisations that invest in this capability now will be positioned to deploy AI faster, with greater confidence, and with demonstrably lower regulatory risk.
If your organisation is beginning this work, start with the inventory and risk classification. If you already have a framework in place, assess its completeness against the four-layer architecture and the NIST AI RMF. The goal is not perfection — it is a defensible, documented, continuously improving governance posture.
Eunoia Consulting Co. specialises in AI governance frameworks for healthcare and veterinary organisations. Our AI Governance Maturity Assessment provides a structured evaluation of your current posture and a prioritised roadmap for improvement.